Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab

by ankyratx1dev | Apr 28, 2025

Ankyra Therapeutics announced preliminary clinical data today from Part 1 of their Phase 1 ANCHOR study evaluating an anchored IL-12 drug conjugate, tolododekin alfa, as monotherapy in patients with solid tumors Ankyra also announced the first patient has been dosed...

Ankyra Therapeutics Announces Expansion of Existing Collaboration to advance IL-12 Anchored Drug Conjugate in Patients with Lung Cancer

by ankyratx1dev | Jan 10, 2025

JANUARY 10, 2025 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotech company developing anchored drug conjugates for the treatment of cancer, today announced an expanded collaboration with Johnson & Johnson* to advance the clinical development of...

Ankyra Therapeutics Announces First Visceral Tumor Patient Dosed in Phase 1 ANCHOR Clinical Trial of ANK-101, an Anchored Interleukin-12 (IL-12)

by Anand Patadiya | Nov 5, 2024

Safety and tolerability to be determined at up to 5 study sites in the United States and Canada November 5, 2024 (Cambridge, MA) – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored therapy to treat cancer, today announced the first...

Ankyra Therapeutics announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. as Chief Medical Officer

by Anand Patadiya | Oct 2, 2024

BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the...

Ankyra Therapeutics Appoints Howard L. Kaufman, M.D. as President and Chief Executive Officer

by Anand Patadiya | Oct 2, 2024

Highly Accomplished Thought Leader with Proven Track Record of Immunotherapy Drug Development BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents, announced today that the Board...